Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24;41(13):2280-2288.
doi: 10.1016/j.vaccine.2023.02.062. Epub 2023 Feb 27.

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France

Cynthia Raissa Tamandjou Tchuem  1 , Vincent Auvigne  2 , Sophie Vaux  3 , Charline Montagnat  4 , Juliette Paireau  5 , Stéphanie Monnier Besnard  6 , Amélie Gabet  7 , Nabil Benhajkassen  8 , Yann Le Strat  9 , Isabelle Parent Du Chatelet  10 , Daniel Levy-Bruhl  11
Affiliations

Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France

Cynthia Raissa Tamandjou Tchuem et al. Vaccine. .

Abstract

The emergence of SARS-CoV-2 variants calls for continuous monitoring of vaccine effectiveness (VE). We estimated the absolute effectiveness of complete 2-dose primary vaccination and booster vaccination with COVID-19 mRNA vaccines, and the duration of protection against Delta and Omicron BA.1 symptomatic infection and severe outcomes. French residents aged ≥50 years, who presented with SARS-CoV-2-like symptoms and tested for SARS-CoV-2 between June 6, 2021 and February 10, 2022 were included. A test-negative study was conducted to estimate VE against symptomatic infection, using conditional logistic regression models. Cox proportional hazard regressions were performed to assess additional protection against severe COVID-19 outcomes (any hospitalization, and intensive care units [ICU] admission or in-hospital death). In total, 273732 cases and 735 919 controls were included. VE against symptomatic infection after 2-doses vaccination was 86% (95% CI: 75-92%) for Delta and 70% (58-79%) for Omicron, 7-30 days post vaccination. Protection waned over time, reaching 60% (57-63%) against Delta and 20% (16.-24%) for Omicron BA.1 > 120 days after vaccination. The booster dose fully restored protection against symtpomatic Delta infection (95% [81-99%]) but only partially against symptomatic Omicron BA.1 infection (63% [59-67%]). VE against Delta-related severe outcomes was above 95% with 2 doses, and persisted for at least four months. Protection against any Omicron BA.1-hospitalization was 92% (65%-99%) at 8-30 days, and 82% (67%-91%) > 120 days from the second dose. Against BA.1 ICU admission or in-patient death, VE stood at 98% (0-100%) at 8-30 days, and was 90% (40-99%) > 120 days from the second dose. Protection confered by mRNA vaccines against severe disease caused by either Delta or Omicron BA.1 appeared high and sustained over time. Protection against symptomatic diseases after 2 doses decreased rapidly, especially against Omicron BA.1. A booster dose restored high protection against Delta but only a partial one against Omicron BA.1.

Keywords: Booster; COVID-19; Effectiveness; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Vaccine effectiveness (all mRNA vaccines combined) against symptomatic COVID-19 disease, any hospitalization and severe hospitalization (ICU admission or in-hospital death) according to the number of doses received and the time since the last dose among ≥50 years old individuals. D1 = first dose of vaccine; D2 = second dose of vaccine.
Fig. 2
Fig. 2
Vaccine effectiveness (all mRNA vaccines combined) against symptomatic COVID-19 disease, any hospitalization and severe hospitalization (ICU admissions or in-hospital deaths) according to the time since last vaccine dose and variant of infection among 50–79 years old individuals. D1 = first dose of vaccine; D2 = second dose of vaccine.
Fig. 3
Fig. 3
Vaccine effectiveness (all mRNA vaccines combined) against symptomatic COVID-19 disease, any hospitalization and severe hospitalization (ICU admissions or in-hospital deaths) according to the time since last vaccine dose and variant of infection among individuals ≥80 years old. D1 = first dose of vaccine; D2 = second dose of vaccine.
See this image and copyright information in PMC

References

    1. Lopez Bernal J., Andrews N., Gower C., Gallagher E., Simmons R., Thelwall S., et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant N Engl J Med. 2021;385:585–594. doi: 10.1056/NEJMoa2108891. - DOI - PMC - PubMed
    1. Charmet T., Schaeffer L., Grant R., Galmiche S., Cheny O., Von Platen C., et al. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Reg Health Eur. 2021;8 doi: 10.1016/j.lanepe.2021.100171. - DOI - PMC - PubMed
    1. Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27:1614-21. doi:10.1038/s41591-021-01446-y. - PubMed
    1. Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–1829. doi: 10.1016/S0140-6736(21)00947-8. - DOI - PMC - PubMed
    1. Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged >/=65 Years - COVID-NET, 13 States, February-April 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1088–93. doi:10.15585/mmwr.mm7032e3. - PMC - PubMed

Supplementary concepts